Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on vaccine development, has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and Great Britain for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (Nasdaq: DVAX), un'azienda biofarmaceutica in fase commerciale focalizzata sullo sviluppo di vaccini, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 20 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e una trasmissione in streaming alle 16:30 ET/13:30 PT lo stesso giorno.
Dynavax commercializza attualmente due prodotti: il vaccino HEPLISAV-B, approvato negli Stati Uniti, nell'UE e nel Regno Unito per la prevenzione del virus dell'epatite B negli adulti di 18 anni e oltre, e l'adjuvante CpG 1018, utilizzato in HEPLISAV-B e in vari vaccini contro il COVID-19.
Dynavax Technologies (Nasdaq: DVAX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de vacunas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 20 de febrero de 2025, después del cierre del mercado en EE. UU. La empresa llevará a cabo una conferencia telefónica y una transmisión en línea a las 4:30 p.m. ET/1:30 p.m. PT el mismo día.
Dynavax actualmente comercializa dos productos: la vacuna HEPLISAV-B, aprobada en EE. UU., la UE y Gran Bretaña para la prevención del virus de la hepatitis B en adultos de 18 años o más, y el adyuvante CpG 1018, utilizado en HEPLISAV-B y en varias vacunas contra el COVID-19.
다이나박스 테크놀로지스 (Nasdaq: DVAX), 백신 개발에 중점을 둔 상업적 단계의 생명공학 회사는 2025년 2월 20일 미국 시장 종료 후 2024년 4분기 및 연간 재무 결과 발표를 예정했습니다. 회사는 같은 날 동부 시간 기준 오후 4시 30분/태평양 시간 기준 오후 1시 30분에 전화 회의 및 웨비나를 주최할 예정입니다.
다이나박스는 현재 두 가지 상업적 제품을 판매하고 있습니다: HEPLISAV-B 백신은 미국, 유럽 연합, 영국에서 성인 18세 이상에 대한 B형 간염 바이러스 예방을 위해 승인되었으며, CpG 1018 보조제는 HEPLISAV-B 및 여러 COVID-19 백신에 사용됩니다.
Dynavax Technologies (Nasdaq: DVAX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de vaccins, annonce que les résultats financiers du quatrième trimestre et de l'année 2024 seront publiés le 20 février 2025, après la fermeture des marchés américains. L'entreprise organisera un appel conférence et un webinaire à 16h30 ET/13h30 PT le même jour.
Dynavax commercialise actuellement deux produits : le vaccin HEPLISAV-B, approuvé aux États-Unis, dans l'UE et en Grande-Bretagne pour la prévention du virus de l'hépatite B chez les adultes de 18 ans et plus, et l'adjuvant CpG 1018, utilisé dans HEPLISAV-B et divers vaccins contre le COVID-19.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Impfstoffentwicklung konzentriert, hat die Bekanntgabe der Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 für 20. Februar 2025 nach Börsenschluss in den USA angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET/13:30 Uhr PT eine Telefonkonferenz und ein Webcast veranstalten.
Dynavax vertreibt derzeit zwei kommerzielle Produkte: den in den USA, der EU und Großbritannien zugelassenen Impfstoff HEPLISAV-B, der zur Vorbeugung des Hepatitis-B-Virus bei Erwachsenen ab 18 Jahren eingesetzt wird, sowie den CpG 1018 Adjuvans, der in HEPLISAV-B und verschiedenen COVID-19-Impfstoffen verwendet wird.
- Has two commercialized products in major markets (HEPLISAV-B and CpG 1018)
- HEPLISAV-B approved in multiple major markets (US, EU, UK)
- None.
Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-february-20-2025-302370741.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax (DVAX) report Q4 and full year 2024 earnings?
What time is Dynavax's (DVAX) Q4 2024 earnings call?
What are Dynavax's (DVAX) main commercial products?
Where is Dynavax's (DVAX) HEPLISAV-B vaccine approved?
